0775:HKG
CK Life Sciences Intl (Holdings) Inc
HK$0.49
arrow_upward
+1.03%(+0.0050) 1D
Oct 28, 4:08:23 PM GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 0775...
Open
HK$0.48
High
HK$0.50
Low
HK$0.48
Mkt. cap
4.66B
Avg. vol.
1.50M
Volume
984.00K
52-wk high
HK$1.02
52-wk low
HK$0.48
EPS
-HK$0.01
Shares outstanding
9.61B
No. of employees
2K
Open
HK$0.48
High
HK$0.50
Low
HK$0.48
Mkt. cap
4.66B
Avg. vol.
1.50M
Volume
984.00K
52-wk high
HK$1.02
52-wk low
HK$0.48
EPS
-HK$0.01
Shares outstanding
9.61B
No. of employees
2K
News stories
From web sources and news partners
kalkine.ca
·
22 minutes ago
FirstSun Capital Bancorp (NASDAQ:FSUN) Q3 2026 Earnings: Returns to Profit as Margin Widens to 3.82%
TradingView
·
1 hour ago
Key facts: NASDAQ:SPCX beats; Bernstein raises PT; $40B GPU debt
Investor's Business Daily
·
4 hours ago
Futures Mixed, Five Key Movers Late; Fed, Microsoft, Google Loom
Reuters
·
13 hours ago
NYSE moves to bring all-or-nothing options to stocks and company earnings
Profile
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Victor Li Tzar-kuoi, the eldest son of Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
About CK Life Sciences Intl (Holdings) Inc